Jeff Yass’s Jasper Therapeutics JSPR Stock Holding History

Jeff Yass’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-372	Closed	-$8.36K	–	13982
2026 Q1	$9.8K	Sell	372 -3,121	-89%	-$130K	﹤0.01%	12942
2025 Q4	$192K	Buy	3,493 +2,307	+195%	+$139K	﹤0.01%	10920
2025 Q3	$84.7K	Sell	1,186 -844	-42%	-$76.8K	﹤0.01%	11657
2025 Q2	$338K	Buy	2,030 +1,494	+279%	+$221K	﹤0.01%	10073
2025 Q1	$69.2K	Sell	536 -224	-29%	-$44.7K	﹤0.01%	11745
2024 Q4	$488K	Buy	760 +76	+11%	+$47.5K	﹤0.01%	8723
2024 Q3	$386K	Buy	+684	New	+$409K	﹤0.01%	9069
2024 Q2	–	Sell	-269	Closed	-$194K	–	12671
2024 Q1	$237K	Buy	+269	New	+$143K	﹤0.01%	10230
2023 Q2	–	Sell	-46	Closed	-$20.5K	–	12641
2023 Q1	$25K	Sell	46 -69	-60%	-$38.3K	﹤0.01%	11978
2022 Q4	$16.3K	Buy	+115	New	+$23.1K	﹤0.01%	11830

Other funds holding JSPR

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return

GSA Capital Partners London, United Kingdom $1.59B AUM 39.8% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jeff Yass's JSPR Position: Q2 2026 in Review

Jeff Yass sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 372 shares — an estimated $8.36K sold.

Jeff Yass first reported a position in JSPR in Q4 2022 and held it in 10 quarters. The position peaked at $488K in Q4 2024. 43 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Jeff Yass reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 372 Jasper Therapeutics shares in Q2 2026, an estimated $8.36K.
Jeff Yass first reported a position in Jasper Therapeutics in Q4 2022 and held it in 10 quarters.
Jeff Yass's Jasper Therapeutics position peaked at $488K in Q4 2024.
43 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.